Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma
B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥ 3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC. The incidence of severe infections was higher with BsAb (40%) than CAR-T (26%) or ADC (8%), including grade 5 infections (7% vs 0% vs 0%, respectively). Comparing T-cell redirecting therapies, the incidence rate of severe infections was significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P = 0.004). During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb. In conclusion, we observed an overall higher and more persistent risk of severe infections with BsAb. Our results also suggest a higher infection risk during periods of hypogammaglobulinemia with BsAb, and with neutropenia in CAR-T recipients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Research square - (2024) vom: 07. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lesokhin, Alexander [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.03.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21203/rs.3.rs-3911922/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368958426 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368958426 | ||
| 003 | DE-627 | ||
| 005 | 20240304232634.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-3911922/v1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM368958426 | ||
| 035 | |a (NLM)38405866 | ||
| 035 | |a (PII)rs.3.rs-3911922 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lesokhin, Alexander |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a B-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥ 3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC. The incidence of severe infections was higher with BsAb (40%) than CAR-T (26%) or ADC (8%), including grade 5 infections (7% vs 0% vs 0%, respectively). Comparing T-cell redirecting therapies, the incidence rate of severe infections was significantly lower with CAR-T compared to BsAb at 1-year (incidence-rate-ratio [IRR] = 0.43, 95%CI 0.25-0.76, P = 0.004). During periods of treatment-emergent hypogammaglobulinemia, BsAb recipients had higher infection rates (IRR:2.27, 1.31-3.98, P = 0.004) and time to severe infection (HR 2.04, 1.05-3.96, P = 0.036) than their CAR-T counterparts. During periods of non-neutropenia, CAR-T recipients had a lower risk (HR 0.44, 95%CI 0.21-0.93, P = 0.032) and incidence rate (IRR:0.32, 95% 0.17-0.59, P < 0.001) of severe infections than BsAb. In conclusion, we observed an overall higher and more persistent risk of severe infections with BsAb. Our results also suggest a higher infection risk during periods of hypogammaglobulinemia with BsAb, and with neutropenia in CAR-T recipients | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Nath, Karthik |e verfasserin |4 aut | |
| 700 | 1 | |a Shekarkhand, Tala |e verfasserin |4 aut | |
| 700 | 1 | |a Nemirovsky, David |e verfasserin |4 aut | |
| 700 | 1 | |a Derkach, Andriy |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Bruno Almeida |e verfasserin |4 aut | |
| 700 | 1 | |a Nishimura, Noriko |e verfasserin |4 aut | |
| 700 | 1 | |a Farzana, Tasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Rueda, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, David |e verfasserin |4 aut | |
| 700 | 1 | |a Landau, Heather |e verfasserin |4 aut | |
| 700 | 1 | |a Lahoud, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Scordo, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Gunjan |e verfasserin |4 aut | |
| 700 | 1 | |a Hassoun, Hani |e verfasserin |4 aut | |
| 700 | 1 | |a Maclachlan, Kylee |e verfasserin |4 aut | |
| 700 | 1 | |a Korde, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Shah, Urvi |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Carlyn Rose |e verfasserin |4 aut | |
| 700 | 1 | |a Hultcrantz, Malin |e verfasserin |4 aut | |
| 700 | 1 | |a Giralt, Sergio |e verfasserin |4 aut | |
| 700 | 1 | |a Usmani, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Shahid, Zainab |e verfasserin |4 aut | |
| 700 | 1 | |a Mailankody, Sham |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Research square |d 2020 |g (2024) vom: 07. Feb. |w (DE-627)NLM312780982 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:07 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-3911922/v1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 07 |c 02 | ||